{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:15:16Z","timestamp":1776352516524,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10096-025-05304-4","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:46:13Z","timestamp":1765881973000},"page":"1221-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees"],"prefix":"10.1007","volume":"45","author":[{"given":"Salvatore","family":"Rotundo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Serapide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Guido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"5304_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02239-4","author":"S Rotundo","year":"2024","unstructured":"Rotundo S, Tassone MT, Serapide F, Russo A, Trecarichi EM (2024) Incipient tuberculosis: a comprehensive overview. Infection. https:\/\/doi.org\/10.1007\/s15010-024-02239-4","journal-title":"Infection"},{"key":"5304_CR2","volume-title":"Licence: CC BY-NC-SA 3.0 IGO","author":"Global tuberculosis report 2024","year":"2024","unstructured":"Global tuberculosis report 2024 (2024) Licence: CC BY-NC-SA 3.0 IGO. World Health Organization, Geneva"},{"issue":"1","key":"5304_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","volume":"211","author":"JJ Saukkonen","year":"2025","unstructured":"Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I et al (2025) Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 211(1):15\u201333. https:\/\/doi.org\/10.1164\/rccm.202410-2096ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"5304_CR4","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE et al (2021) Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 384(18):1705\u20131718. https:\/\/doi.org\/10.1056\/NEJMoa2033400","journal-title":"N Engl J Med"},{"key":"5304_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05301-7","author":"S Rotundo","year":"2025","unstructured":"Rotundo S, Serapide F, D\u2019Ettorre G, Tassone MT, Albanese M, Marino GG, Tassone B, Ceccarelli G, Russo A (2025) Managing tuberculosis infection among migrants from high-incidence tuberculosis countries: challenges, strategies and recommendations. Eur J Clin Microbiol Infect Dis. https:\/\/doi.org\/10.1007\/s10096-025-05301-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"5304_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S1473-3099(23)00372-9","volume":"23","author":"S Litvinjenko","year":"2023","unstructured":"Litvinjenko S, Magwood O, Wu S, Wei X (2023) Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews. Lancet Infect Dis 23(12):1395\u20131407. https:\/\/doi.org\/10.1016\/S1473-3099(23)00372-9","journal-title":"Lancet Infect Dis"},{"key":"5304_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107279","volume":"150","author":"F Di Gennaro","year":"2025","unstructured":"Di Gennaro F, Cotugno S, Guido G, Cavallin F, Pisaturo M, Onorato L et al (2025) Disparities in tuberculosis diagnostic delays between native and migrant populations in Italy: a multicenter study. Int J Infect Dis 150:107279. https:\/\/doi.org\/10.1016\/j.ijid.2024.107279","journal-title":"Int J Infect Dis"},{"key":"5304_CR8","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.ijregi.2024.100564","volume":"14","author":"C Sergio","year":"2025","unstructured":"Sergio C, Giacomo G, Vladimiro SF, Luisa F, Roberta P, Vincenzo G et al (2025) Tuberculosis outcomes among international migrants living in Europe compared with the nonmigrant population: A systematic review and meta-analysis. IJID Reg 14:100564. https:\/\/doi.org\/10.1016\/j.ijregi.2024.100564","journal-title":"IJID Reg"},{"key":"5304_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00388-2022","author":"L Guglielmetti","year":"2022","unstructured":"Guglielmetti L, Gunther G, Leu C, Cirillo D, Duarte R, Garcia-Basteiro AL (2022) Rifapentine access in europe: growing concerns over key tuberculosis treatment component. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00388-2022","journal-title":"Eur Respir J"},{"issue":"6","key":"5304_CR10","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1016\/S2214-109X(24)00088-3","volume":"12","author":"TS Ryckman","year":"2024","unstructured":"Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, Mirzayev F et al (2024) Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. Lancet Glob Health 12(6):e995\u2013e1004. https:\/\/doi.org\/10.1016\/S2214-109X(24)00088-3","journal-title":"Lancet Glob Health"},{"key":"5304_CR11","volume-title":"Guidelines on the management of latent tuberculosis infection","author":"World Health Organization","year":"2025","unstructured":"World Health Organization (2025) Guidelines on the management of latent tuberculosis infection. WHO, Geneva"},{"issue":"10","key":"5304_CR12","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3201\/eid2910.230314","volume":"29","author":"CA Winston","year":"2023","unstructured":"Winston CA, Marks SM, Carr W (2023) Estimated costs of 4-month pulmonary tuberculosis treatment regimen, united States. Emerg Infect Dis 29(10):2102\u20132104. https:\/\/doi.org\/10.3201\/eid2910.230314","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"5304_CR13","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1186\/s12889-022-14766-6","volume":"22","author":"WA Lai","year":"2022","unstructured":"Lai WA, Brethour K, D\u2019Silva O, Chaisson RE, Zwerling AA (2022) Cost-effectiveness of 3-months Isoniazid and rifapentine compared to 9-months Isoniazid for latent tuberculosis infection: a systematic review. BMC Public Health 22(1):2292. https:\/\/doi.org\/10.1186\/s12889-022-14766-6","journal-title":"BMC Public Health"},{"key":"5304_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01128-2018","author":"G Froberg","year":"2019","unstructured":"Froberg G, Jansson L, Bruchfeld J (2019) Treatment of latent tuberculosis with 12 weeks isoniazid\/rifapentine in clinical practice. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01128-2018","journal-title":"Eur Respir J"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05304-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:33:57Z","timestamp":1776350037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05304-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5304"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05304-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no ethical conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}